Fecal Calprotectin Test Market Size & Growth Forecast 2026–2035, By Segments (Assay, Application, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Fecal Calprotectin Test Market size was around USD 5.53 Billion in 2025 and is slated to grow at a 11.1% CAGR from 2026 to 2035, surpassing USD 15.84 Billion by 2035. The industry revenue for 2026 is calculated at USD 6.07 billion.
Get more details on this report
Request Free Sample ReportFecal Calprotectin Test Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 48.97% share due to strong diagnostic infrastructure, widespread clinical use of noninvasive GI testing, and routine integration into hospital and laboratory workflows.
- Asia Pacific grows at 12.43% CAGR driven by improving lab access, rising GI disorder diagnosis, and increasing adoption of noninvasive biomarkers in routine gastroenterology practice.
Segment Momentum
- ELISA leads with 64.41% share due to strong clinical adoption, laboratory familiarity, and reliable integration into routine workflows for consistent intestinal inflammation biomarker testing.
- Colorectal cancer is the fastest-growing application as demand rises for non-invasive testing approaches that support early assessment, patient triage, and reduced reliance on invasive diagnostic procedures.
Market Expansion Drivers
- Rising prevalence of IBD and IBS increasing demand for non-invasive gastrointestinal diagnostics.
- Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times.
- Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the fecal calprotectin test market include Abbott Laboratories (USA), Thermo Fisher Scientific Inc. (USA), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux SA (France), BÜHLMANN Laboratories AG (Switzerland), DiaSorin S.p.A. (Italy), ALPCO Diagnostics (USA), Eagle Biosciences, Inc. (USA), Svar Life Science AB (Sweden), DRG International, Inc. (USA).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As IBD and IBS diagnoses become more common, clinicians are under greater pressure to distinguish inflammatory disease from functional gastrointestinal disorders without relying immediately on colonoscopy for every symptomatic patient. That dynamic is increasing demand for the fecal calprotectin test market because the test helps triage patients, support referral decisions, and monitor inflammatory activity using a non-invasive sample collection method that fits routine care pathways more easily than endoscopic evaluation. Rising patient volumes also push providers and payers toward diagnostic approaches that can reduce unnecessary invasive procedures, reinforcing market demand for fecal calprotectin testing as a practical first-line tool in gastrointestinal assessment.
Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times
Improvements in point-of-care platforms are changing how quickly gastrointestinal symptoms can be assessed, which is driving market development in the fecal calprotectin test market by bringing testing closer to the patient and shortening the delay between presentation and clinical action. Faster turnaround allows physicians to make earlier decisions on referral, treatment adjustment, or additional investigation, which is especially relevant when managing suspected inflammatory flare-ups or persistent symptoms in outpatient settings. As these technologies become easier to use and more compatible with decentralized care delivery, they support broader test adoption among clinics that need actionable results without depending on centralized laboratory workflows.
Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions
The shift toward home-based sample collection is increasing market presence in the fecal calprotectin test market by aligning testing with long-term disease monitoring and patient convenience. For individuals managing chronic gastrointestinal conditions, home-based kits reduce the friction associated with repeated clinic visits and make follow-up testing more feasible, which can improve adherence to monitoring schedules recommended by physicians. This practical ease matters commercially because it expands testing beyond initial diagnostic workups into ongoing disease management, encouraging market growth through more frequent use in patient-centric care models.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of IBD and IBS increasing demand for non-invasive gastrointestinal diagnostics | 2.10% | Moderate | North America, Europe | High | Near Term |
| Advancements in point-of-care diagnostic technologies improving accessibility and turnaround times | 1.80% | Moderate | Asia Pacific, North America | High | Mid Term |
| Growing adoption of home-based diagnostic kits expanding patient-centric gastrointestinal monitoring solutions | 1.50% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional share of the fecal calprotectin test market in 2025, accounting for 48.97% share. This position is bolstered by established diagnostic testing infrastructure, broad physician familiarity with noninvasive gastrointestinal biomarker assessment, and routine use of laboratory-based workflows that can absorb fecal calprotectin testing into everyday clinical practice. The region’s market activity is also strengthened by consistent demand for tools that help differentiate inflammatory bowel disease from other gastrointestinal conditions, which keeps testing volumes tied closely to practical diagnostic decision-making across hospitals, specialty clinics, and reference laboratories.
Asia Pacific is projected to expand at a 12.43% CAGR over the forecast period in the fecal calprotectin test market. Growth is being propelled by rising adoption of advanced gastrointestinal diagnostics, improving access to laboratory services, and expanding clinical attention to earlier and more efficient evaluation of digestive disorders. As healthcare systems across the region strengthen testing capacity and clinicians increasingly use noninvasive methods to support diagnosis and monitoring, demand is moving from limited use cases toward broader incorporation in routine gastroenterology practice.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants/Startups i Scale Low Medium High | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Testing PrecisionGermany emphasizes high-quality fecal calprotectin testing supported by standardized laboratory workflows and reliable diagnostic performance. Clinical laboratories in Germany prioritize consistent analytical accuracy to strengthen gastrointestinal disease assessment and patient management.
France 🇫🇷
Gastrointestinal Care SupportFrance integrates fecal calprotectin testing into routine gastrointestinal diagnostics to assist with patient assessment and ongoing disease monitoring. Healthcare professionals in France prioritize validated testing methods that support efficient clinical decision-making and optimized patient management.
Italy 🇮🇹
Clinical Monitoring SolutionsItaly strengthens the use of fecal calprotectin testing in gastroenterology by supporting non-invasive monitoring of inflammatory bowel disorders. Laboratories and healthcare providers in Italy emphasize dependable assay performance and efficient integration into routine diagnostic workflows.
Japan 🇯🇵
Early Disease AssessmentJapan incorporates fecal calprotectin testing into gastroenterology practice to improve evaluation of intestinal inflammation and treatment monitoring. Healthcare providers in Japan focus on dependable diagnostic methods that enhance clinical efficiency and patient care pathways.
South Korea 🇰🇷
Diagnostic Workflow EfficiencySouth Korea continues expanding fecal calprotectin testing as healthcare providers seek faster, evidence-based approaches to gastrointestinal disease evaluation. Clinical laboratories in South Korea emphasize automated testing platforms that improve turnaround time and diagnostic consistency.
United States 🇺🇸
Non-Invasive DiagnosticsThe U.S. increasingly adopts fecal calprotectin testing to support early assessment and monitoring of inflammatory bowel conditions. Healthcare providers in the U.S. value accurate, non-invasive diagnostic tools that help reduce unnecessary invasive procedures and improve clinical decision-making.
Segment Leadership and Growth Trends
Fecal Calprotectin Test Market Share (%), Assay, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the fecal calprotectin test market, Enzyme-linked Immunosorbent Assay held the leading position in 2025 with a 64.41% share. Its continued dominance is tied to established clinical use, broad laboratory familiarity, and routine adoption in diagnostic workflows where consistent processing of stool biomarkers is required. The segment benefits from being deeply embedded in testing protocols for intestinal inflammation assessment, which helps sustain its share across hospital and diagnostic laboratory settings.
Enzyme Fluroimmunoassay is the fastest-growing assay segment in the fecal calprotectin test market as laboratories increasingly look for methods that better align with evolving efficiency and throughput needs. Its growth momentum is supported by rising demand for faster and more streamlined testing processes, especially in settings where quicker turnaround can improve patient management decisions. Compared with more established alternatives, Enzyme Fluroimmunoassay is gaining traction because it fits more readily into modernized diagnostic operations.
Application Segment Analysis: Inflammatory Bowel Disease (Largest Segment) vs Colorectal Cancer (Fastest-Growing Segment)
In 2025, Inflammatory Bowel Disease accounted for the largest application segment in the fecal calprotectin test market, capturing a 64.02% share. This leadership is underpinned by the test’s practical role in evaluating intestinal inflammation and supporting ongoing disease monitoring in routine care pathways. Since fecal calprotectin testing is closely associated with the assessment and management of inflammatory bowel conditions, this application continues to command the largest share of demand.
Colorectal Cancer represents the fastest-growing application in the fecal calprotectin test market, driven by expanding interest in non-invasive tools that can support earlier clinical evaluation and patient triage. Growth in this segment reflects increasing use of fecal biomarker testing in scenarios where reducing unnecessary invasive procedures and improving initial assessment efficiency are becoming more important. Relative to more established application areas, colorectal cancer is gaining momentum because screening-oriented and diagnostic support needs are broadening the use case for fecal calprotectin testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Assay | Enzyme-linked Immunosorbent Assay, Enzyme Fluroimmunoassay, Quantitative Immunochromatography | Enzyme-linked Immunosorbent Assay | Enzyme Fluroimmunoassay |
| Application | Inflammatory Bowel Disease, Colorectal Cancer, Others | Inflammatory Bowel Disease | Colorectal Cancer |
| End-use | Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutes | Hospitals and Clinics | Diagnostic Laboratories |
Competitive Landscape and Market Positioning
1. Abbott Laboratories (USA)
2. Thermo Fisher Scientific Inc. (USA)
3. F. Hoffmann-La Roche Ltd (Switzerland)
4. bioMérieux SA (France)
5. BÜHLMANN Laboratories AG (Switzerland)
6. DiaSorin S.p.A. (Italy)
7. ALPCO Diagnostics (USA)
8. Eagle Biosciences Inc. (USA)
9. Svar Life Science AB (Sweden)
10. DRG International Inc. (USA)
The fecal calprotectin test market is expanding as healthcare providers increasingly adopt non-invasive diagnostic methods for gastrointestinal disease assessment. Diagnostic developers are focusing on improving test sensitivity, automation compatibility, and result turnaround times to support faster clinical decision-making. Technological enhancements in biomarker detection and laboratory workflow integration are also contributing to greater adoption across healthcare facilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Various Manufacturers | Jan-26 | Research presented at the 2026 Crohn’s & Colitis Congress highlighted critical assay variability in FDA-cleared fecal calprotectin tests. Findings indicated significant discrepancies in reference ranges and specificity across methodologies, suggesting that inconsistent performance may contribute to false positives and unnecessary follow-up colonoscopies, highlighting the need for improved standardization in diagnostic sensitivity and clinical application. |
| Eiken Chemical | 2026 | Eiken Chemical continues to expand the global adoption of the OC-SENSOR Ceres™ analyzer, which integrates fecal immunochemical testing (FIT) and calprotectin measurement on a single platform. This combined testing capability streamlines clinical workflows by allowing patients to use a single collection bottle for both assays, reducing laboratory processing steps and improving diagnostic turnaround times for IBD screening. |
| Various Payers | 2025 | Reflecting the clinical utility of calprotectin as a non-invasive biomarker, major health plans updated their medical policies throughout 2025 and early 2026 to formalize coverage for fecal calprotectin testing. These policies standardize the use of the test for the differential diagnosis of IBD versus IBS and for ongoing monitoring of disease activity, confirming its role as a surrogate marker for endoscopic remission. |
| Biohit | 2025 | Biohit continues to emphasize the clinical value of its quantitative calprotectin assays as an essential component of its digestive health diagnostic toolkit. The company focuses on the diagnostic utility of the test in differentiating inflammatory conditions from functional bowel disorders, actively supporting the shift toward non-invasive biomarkers to reduce the burden of unnecessary diagnostic investigations. |
| DiaSorin | 2022 | DiaSorin leverages the LIAISON® Calprotectin assay, a chemiluminescent-based test that remains a key component of its non-invasive IBD screening portfolio. The platform's capability to integrate with automated sample preparation devices, such as the LIAISON Q.S.E.T. Device Plus, continues to support laboratory efficiency by standardizing the pre-analytical phase of fecal sample handling. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Fecal Calprotectin Test Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Fecal Calprotectin Test Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of fecal calprotectin test?
What is the forecasted size of the fecal calprotectin test industry?
How is the rising prevalence of gastrointestinal disorders influencing diagnostic strategies in the fecal calprotectin test market?
How are point-of-care and home-based testing trends changing patient monitoring in the fecal calprotectin test market?
Why does ELISA dominate the fecal calprotectin test market?
What is driving growth in colorectal cancer applications?
Why is North America the leading region in this market?
What is driving growth in Asia Pacific fecal calprotectin testing?
Which companies dominate the fecal calprotectin test landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization